Himani Goyal, MD, takes glaucoma care to the next level by embracing advancements that extend beyond traditional treatment ...

Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two U.S. Phase II clinical trials ...

Latanoprost ophthalmic solution 0.005% with 0.02% BAK or travoprost 0.004% ophthalmic solution with sofZia were tested against the following bacteria and fungi: Staphylococcus aureus (ATCC 6538 ...

But the most common treatment is pressure-reducing eye drops, which are applied once or twice a day. These include low-strength drops, such as bimatoprost or latanoprost. If these do not work ...